JelloX Biotech Inc.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
JelloX has launched the first product “JX ACE 3D Pathology Imaging Service” to provide customers high resolution pathology images. Special advantages including high accuracy, convenience and efficiency make it a rapid and economic commercialized 3D pathol
The content above was translated by Ai
Founded Year
2018
Unified Business No.
54958394
Status
Active
Number of Employees
0
Total Paid-in
Capital
49,426,680 (NT$)
Location of Company
Taiwan
, Hsinchu County
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
JelloX Biotech Inc. is a university startup by research team from National Tsing Hua University. JelloX owns exclusive in-license and invention patents to develop innovative digital imaging technology and AI analysis platform for next generation pathology with 3D digital pathology image and tissue feature-based diagnosis. We aim at creation of the world first 3D digital pathology solution in support of precision cancer diagnosis, optimize patient treatment outcome, and matching right patients with right drugs at right time. Our slogan is “Reimaging Pathology at New Horizon”
The content above was translated by Ai
